CNR1 and myeloid sarcoma: In fact, it is well-known that glutamate is a key mediator in neuronal and oligodendrocyte damage in MS [91], and CB1R agonists exert direct neuroprotective effects by limiting glutamate release and the excitotoxic damage characteristic of several neurodegenerative disorders [92].